VASCULAR COMPLICATIONS IN LONG COVID ARE VERY RARE

Igor  Končar

doi:10.5937/mp74-48049

Igor Končar Univerzitet u Beogradu, Medicinski fakultet, Beograd, Srbija; Univerzitetski klinički centar Srbije, Klinika za vaskularnu i endovaskularnu hirurgiju, Beograd, Srbija

DOI: https://doi.org/10.5937/mp74-48049

Keywords: vascular complications, thrombosis, ischemia, pulmory embolism, vein thrombosis, arterial thrombosis, emoblisation, long COVID

Abstract

Depending on the methodology thrombotic events during the acute COVID-19 infection were noted from 20-85%. Following the acute phase of the disease, it was noted that a subgroup of patients had various non-specific, prevailing symptoms for weeks, or even months and such a condition was accepted as a long COVID. Having in mind mechanisms of vascular complications in acute COVID infection and pathogenesis of long COVID, one would expect similar presentation and consequences of long COVID on human vasculature.

We conducted a wide search of the literature on the topic and after screening of titles and abstracts papers with potential inclusion of the data regarding long COVID and vascular symptoms or complications that occurred during the time span of more than then 4 weeks after COVID infection.

Research dealing with long COVID are mostly focused on symptoms and laboratory findings due to the nature of this condition. Data regarding vascular complications in these studies are either missing or the incidence of vascular complications was very low. Very few manifestations were related to cardiovascular system and D-dimer was assessed in only two studies showing increased values from very lot to almost in 30% of patients after COVID infection. Finally, in comparison of vascular complications with other viral infections in Sweden on patients undergoing diagnostic tests for venous thromboembolism increased risk for VTE in COVID-positive patients was proved. In the group of patients with chronic cardiovascular disease, the risk of arterial and venous thrombotic events after COVID infection is substantially higher. In comparison with seasonal influenza burden with coagulation disorders, pulmonary embolism, acute phlebitis, thrombophlebitis or thromboembolism and arterial embolism were higher and cumulative incidence was reported from 0.6-5.5% while hazard ration was from 2-18.

Based on the published literature, vascular complications in the long COVID are very rare. Comparing to a very high rate of thrombotic events in the acute COVID infection and their correlation with severity of clinical presentation of COVID infection, the role and presence of vascular complications in long COVID is without any significance. Future studies focusing on the pathophysiology of long COVID could probably reveal potential mechanisms and explanations for such a difference.

References

Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020;18(6):1421-4.
2. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research. 2020;191:145–7.
3. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-COV-2 infection: A multicenter prospective cohort study. Intensive Care Medicine. 2020;46(6):1089–98.
4. Perini P, Nabulsi B, Massoni CB, Azzarone M, Freyrie A. Acute limb ischaemia in two young, non-atherosclerotic patients with covid-19. The Lancet. 2020;395(10236):1546.
5. Llitjos J, Leclerc M, Chochois C, Monsallier J, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. Journal of Thrombosis and Haemostasis. 2020;18(7):1743–6.
6. Yousefi P, Soltani S, Siri G, Rezayat SA, Gholami A, Zafarani A, et al. Coagulopathy and thromboembolic events a pathogenic mechanism of COVID‐19 associated with mortality: An updated review. Journal of Clinical Laboratory Analysis. 2023;37(11–12).
7. Venkatesan P. Nice guideline on Long Covid. The Lancet Respiratory Medicine. 2021;9(2):129.
8. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. MMWR Morbidity and Mortality Weekly Report. 2020;69(30):993–8.
9. Daher A, Balfanz P, Cornelissen C, Müller A, Bergs I, Marx N, et al. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respiratory Medicine. 2020;174:106197.
10. Klein H, Asseo K, Karni N, Benjamini Y, Nir-Paz R, Muszkat M, et al. Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: A cohort study in Israeli patients. Clinical Microbiology and Infection. 2021;27(5):769–74.
11. Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nature Immunology. 2022;23(2):194–202.
12. Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, et al. Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC: Cardiovascular Imaging. 2021;14(11):2155–66.
13. Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. Gastrointestinal symptoms and fecal shedding of SARS-COV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3(6).
14. Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, et al. Long-term SARS-COV-2-specific immune and inflammatory responses in individuals recovering from covid-19 with and without post-acute symptoms. Cell Reports. 2021;36(6):109518.
15. Littlefield KM, Watson RO, Schneider JM, Neff CP, Yamada E, Zhang M, et al. SARS-COV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-COV-2. PLOS Pathogens. 2022;18(5).
16. Jing H, Wu X, Xiang M, Liu L, Novakovic VA, Shi J. Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Frontiers in Immunology. 2022;13.
17. Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, et al. Persistent endotheliopathy in the pathogenesis of Long Covid syndrome. Journal of Thrombosis and Haemostasis. 2021;19(10):2546–53.
18. Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022 Feb 17;479(4):537-559.
19. Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: Nationwide self-controlled cases series and matched Cohort Study. BMJ. 2022;
20. Marjenberg Z, Leng S, Tascini C, Garg M, Misso K, El Guerche Seblain C, et al. Risk of long COVID main symptoms after SARS-COV-2 infection: A systematic review and meta-analysis. Scientific Reports. 2023;13(1).
21. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo P, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. 2021;
22. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. ‘long-COVID’: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020;76(4):396–8.
23. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in Covid‐19. Journal of Thrombosis and Haemostasis. 2020;18(9):2103–9.
24. Baldini T, Asioli GM, Romoli M, Carvalho Dias M, Schulte EC, Hauer L, et al. Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus‐2 infection: A systematic review and meta‐analysis. European Journal of Neurology. 2021;28(10):3478–90.
25. Wretborn J, Jörg M, Benjaminsson Nyberg P, Wilhelms DB. Risk of venous thromboembolism in a Swedish healthcare system during the COVID‐19 pandemic: A retrospective cross‐sectional study. Journal of the American College of Emergency Physicians Open. 2021;2(5).
26. Giannis D, Goldin M, Rahman H, Sison CP, Lesser ML, Ngu S, et al. Risk factors for postdischarge major thromboembolism and mortality in hospitalized patients with COVID-19 with cardiovascular comorbidities: Insights from the CORE-19 Registry. Thrombosis and Haemostasis. 2023;123(11):1089–99.
27. Yong SJ, Liu S. Proposed subtypes of post‐covid‐19 syndrome (or long‐covid) and their respective potential therapies. Reviews in Medical Virology. 2021;32(4).
28. Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, et al. Postdischarge thrombosis and hemorrhage in patients with covid-19. Blood. 2020;136(11):1342–6.
29. Sjoland H, Lindgren M, Toska T, Hansson PO, Sandblad KG, Alex C, et al. Pulmonary embolism and deep venous thrombosis after COVID-19: long-term risk in a population-based cohort study. European Heart Journal. 2023;7(5):100284.
30. Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Seminars in Thrombosis and Hemostasis. 2021;47(04):362–71.
31. Remy-Jardin M, Duthoit L, Perez T, Felloni P, Faivre J-B, Fry S, et al. Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-COV-2 pneumonia: Dual-energy CT (DECT) angiographic study in 55 patients. EClinicalMedicine. 2021;34:100778.
32. Fan BE, Umapathi T, Chua K, Chia YW, Wong SW, Tan GW, et al. Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients. Journal of Thrombosis and Thrombolysis. 2020;51(4):971–7.